
Prolonged response after stopping TPO-RA in ITP, TP53 mutations and myelofibrosis outcomes, clinical picture of ERCC6L2 disease, where variants predispose to marrow failure and malignancy
Blood Podcast
00:00
Introduction
Learn more about the impact of TP53 on the outcomes of patients with myelofibrosis following hematopoietic stem cell transplant. Review the comprehensive clinical picture of the ERCC 6L2 disease, where germline variants predispose to marrow failure and myeloid malignancies. Discuss findings from a prospective trial assessing response after discontinuation of T-Po receptor agonist therapy in ITP.
Transcript
Play full episode